|
AU2014274536A1
|
|
Benzene or thiophene derivative and use thereof as vap-1 inhibitor
|
|
AU2013203609A1
|
|
Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby
|
|
AU2013203279A1
|
|
Pharmaceutical composition for the treatment of dry eye and/or corneal/conjunctival disorders
|
|
WO2013005819A1
|
|
Method for preparing a fatty acid derivative
|
|
TW201309660A
|
|
Method for preparing a fatty acid derivative
|
|
KR20140048196A
|
|
Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases
|
|
EP2700429A1
|
|
Drug solution applicator
|
|
KR20140038404A
|
|
Aqueous ophthalmic composition
|
|
US2011275711A1
|
|
Method for treating macular edema
|
|
AU2010323566A1
|
|
Method for screening drug efficacious in treating dry eye and/or keratoconjunctival disorders and pharmaceutical composition obtained thereby
|
|
TW201113022A
|
|
Composition for ocular local-administration for treating ocular hypertension and glaucoma
|
|
US2010087540A1
|
|
Pharmaceutical composition
|
|
TW201000473A
|
|
Benzene or thiophene derivative and use thereof as vap-1 inhibitor
|
|
NZ602479A
|
|
Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
|
|
TW200934488A
|
|
Thiazole derivative and use thereof as vap-1 inhibitor
|
|
CA2702885A1
|
|
Pharmaceutical composition for treatment of cataract
|
|
CA2691995A1
|
|
Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
|
|
CA2691520A1
|
|
Composition for ophthalmic disease associated with hypoxia or ischemia
|
|
WO2008133021A1
|
|
COMPOSITION FOR AMELIORATING OPTIC NERVE DISORDER COMPRISING PROSTAGLANDIN F2α COMPOUND AS ACTIVE INGREDIENT
|
|
TW200835687A
|
|
Thiazole derivatives and their use as VAP-1 inhibitor
|
